

Article

Does Cannabidiol (CBD) in Food Supplements Pose a Serious Health Risk? Consequences of the European Food Safety Authority (EFSA) Clock Stop Regarding Novel Food Authorisation

Dirk W. Lachenmeier*, Constanze Sproll, Patricia Golombek and Stephan G. Walch

Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Weissenburger Strasse 3, 76187 Karlsruhe, Germany; constanze.sproll@cvuaka.bwl.de (C.S.); patricia.golombek@cvuaka.bwl.de (P.G.); stephan.walch@cvuaka.bwl.de (S.G.W.)

* Correspondence: lachenmeier@web.de; Tel.: +49-721-926-5434

Abstract: In the European Union (EU), cannabidiol products require pre-marketing authorisation under the novel food regulation. Currently, 19 CBD applications are under assessment at the European Food Safety Authority (EFSA). During the initial assessment of the application files, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) located several knowledge gaps in their 07 June 2022 statement on safety of cannabidiol as a novel food that need to be addressed before the evaluation of CBD can be concluded. Namely, the effect of CBD on the liver, gastrointestinal tract, endocrine system, nervous system, psychological function, and reproductive system needs to be clarified. Nevertheless, the available literature allows a benchmark dose (BMD)-response modelling of several bioassays, resulting in a BMD lower confidence limit (BMDL) of 20 mg/kg bw/day for liver toxicity in rats. Human data in healthy volunteers found increases in the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in a study at 4.3 mg/kg bw/day, which was defined by EFSA NDA panel as a lowest observed adverse effect level (LOAEL). The EFSA NDA panel currently concluded that the safety of CBD as a novel food cannot be evaluated, leading to a so-called clock stop of the applications until the applicants provide the required data. Meanwhile, the authors suggest that CBD products still available as food supplements on the EU market despite the lack of authorisation must be considered as “unsafe”. Products exceeding a health-based guidance value of 10 mg/day must be considered as being “unfit for consumption” (Article 14(1) and (2) (b) of Regulation No 178/2002), while the ones in exceedance of the human LOAEL must be considered “injurious to health” (Article 14(1) and (2) (a) of Regulation No 178/2002).

Keywords: food safety; risk assessment; *Cannabis sativa*; tetrahydrocannabinol; food supplements; cannabidiol; benchmark dose; health-based guidance value (HBGV); liver toxicity

1. Introduction

In the European Union (EU), foods and food ingredients evaluated as novel need a pre-marketing approval in the form of an implementing regulation issued by the European Commission (EC) [1]. Before that, the European Food Safety Authority (EFSA) is asked to provide a risk assessment for the novel food, on which the EC decision is based. The novelty of a food is determined by a lack of significant history of consumption prior to 15 May 1997 [2]. Regarding the hemp plant *Cannabis sativa* L., only the seeds and seed-derived products have a history of consumption and are treated as “not novel”. In contrast, extracts and derived products containing cannabinoids, such as cannabidiol (CBD), but also synthetic cannabinoids are considered novel foods [3]. Hence, CBD products, which are intended to be marketed as foods or food supplements in the EU, need prior

authorisation. Despite being widely advertised and sold in increasing quantities, all available CBD oils and CBD-containing food supplements in the EU are, therefore, currently placed on the market with an infringement of the food laws [4]. This is not a niche anymore as the total EU CBD market was valued at EUR 1.6 billion in 2020 [5]. Apparently, it is a worldwide phenomenon that illegality is not a deterrent for producers, as CBD food products may be readily available in jurisdictions where they are illegal because jurisdictional enforcement is lenient [6].

As of mid-March 2022, the industry has so far provided more than 150 novel food applications for CBD products and 19 are currently under assessment by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Most of the applications are for CBD extracted from hemp plants, but there are also several applications with chemically synthesised CBD [7].

During the initial assessment of the application files, the EFSA NDA panel located several knowledge gaps that need to be addressed before the safety evaluation of CBD can be concluded. Namely, the effect of CBD on the liver, gastrointestinal tract, endocrine system, nervous system, psychological function, and reproductive system needs to be clarified [7]. One of the major adverse effects of CBD at therapeutic dosages appears to be liver injury, which may lead to symptoms of hepatitis even in healthy adults [8]. Literature was searched and reviewed by the EFSA NDA panel, but no observed adverse effect level (NOAEL) could not be identified in both animal and human studies [7]. The EFSA NDA panel currently concluded that the safety of CBD as a novel food cannot be evaluated, leading to a so-called clock stop of the applications until the applicants provide the required data [7].

This article aims to provide an in-depth look into the available data about CBD and provide an interim judgement about the risk of products currently on the market. As NOAEL were not available or uninformative, benchmark dose-response modelling of the data highlighted by EFSA NDA panel was conducted to provide an alternative point of departure (POD) for toxicological risk assessment.

2. Materials and Methods

The data analysed in this study were obtained from the statement of the EFSA NDA panel [7]. No additional searches for data were conducted, apart from inclusion of another informative study of Dziwenka et al. [9] not included in the EFSA statement [7].

The data were checked for the suitability of benchmark dose-response modelling according to the criteria of Hindelang et al. [10]: (i) a study considered for inclusion in this research had to have administered at least 3 different doses and a control group receiving vehicle, while dose spacing was not considered relevant, (ii) applied doses had to be administered in mg/kg of body weight, (iii) the number of animals per dose group had to be declared, and (iv) studies reporting concomitant treatment with other medications were not included.

The eligible studies were then assessed using the benchmark dose (BMD) approach according to the guidelines of the United States (US) Environmental Protection Agency (EPA) [11]. The BMD and its respective lower confidence interval, the BMDL, were calculated by fitting multiple statistical models using the US EPA benchmark dose v. 3.2.0.1 (rel. 2022-03-15) software (BMDS) [12], which performs automated fitting of selected models to dose-response data retrieved from toxicological studies. The most suitable model was determined based on the Akaike information criteria generated in the output. All settings of BMDS were at default.

3. Results

From the studies assessed by the EFSA NDA panel [7], only 3 animal studies were identified with suitable dose-response data for benchmark dose modelling, and additionally a study of Dziwenka et al. [9] was included. Two of the studies (GWTX1412 and

GWTX1413) were published in the context of the approval process of the CBD medicinal product Epidiolex as part of the application review files on the US Food and Drug Administration (FDA) website [13]. Another study, by Marx et al. [14], was published in the peer-reviewed literature, but the test object was a hemp extract and not isolated CBD. As the extract was of a comparably high purity of CBD, the authors decided to still include the study for comparative reasons. Similarly, Dziwenka et al. [9,15] recently provided 2 studies of hemp extracts; while the 2020 study [15] did not provide raw data necessary for BMD modelling, the 2021 study [9] was included for comparative reasons as well.

The results of the dose-response modelling are presented in Table 1. An example for the BMD modelling of the GWTX1412 study, which was judged as being the most informative, is shown in Figure 1. The full BMD modelling reports of all studies included in Table 1 are provided as supplementary materials (documents S1-S5).

Table 1. Dose-response modelling results for cannabidiol (CBD) in different animal experiments.

Study, animal model	Study design, CBD doses	Endpoint	Sex	Model ^a	<i>p</i> -value ^b	BMD ^c (mg/kg bw/day)	BMDL ^d (mg/kg bw/day)
GWTX1412 [13], rats	26-week oral at doses of 0, 15, 50, and 150 mg/kg bw/day (n=15/sex/group)	Liver, centrilobular hypertrophy ^e	Males + females combined ^f	Dichotomous Hill	0.9989	41	20
GWTX1413 [13], dogs	39-week oral at doses of 0, 10, 50, and 100 mg/kg bw/day (n=4/sex/group)	Liver, hepatocyte hypertrophy ^e	Males + females combined ^f	Log-Probit	0.5771	(3) ^g	(2) ^g
Marx et al. [14], rats	90-day oral at doses of 0, 25, 90, and 180 mg/kg bw/day (n=10/sex/group) ^h	Liver weight	Males ⁱ	Exponential ₂	0.5235	(52) ^j	(43) ^j
			Females ⁱ	Polynomial ₃	0.9771	(52) ^j	(34) ^j
Dziwenka et al. [9], rats	90-day oral at doses of 0, 6.3, 22.7 and 81.6 mg/kg bw/day (n=10/sex/group) ^k	Relative liver weight	Females	Exponential ₂	0.1941	(39) ^j	(26) ^j

^a Data of the viable recommended model selected with BMDS 3.2.0.1 (rel. 2022-03-15) software are presented. ^b A *p*-value greater than 0.1 indicated that the model fits the data (*p*-value 1.0 = perfect fit). ^c BMD: benchmark dose for a benchmark response of 1 standard deviation (continuous models) or 10% extra risk (dichotomous data). ^d BMDL: 95% lower one-sided confidence limit of the BMD. ^e The sum of incidences for all grades of liver effects was evaluated. ^f A single curve is fitted to both sexes as the analysis revealed no significant differences in dose-response between the sexes. ^g BMD and BMDL are both 3x lower than the lowest non-zero dose and the model must be cautiously interpreted. ^h The study of Marx et al. [14] was conducted with a hemp extract containing 26% of cannabinoids of which 96% is CBD. The dose levels were adjusted to reflect pure CBD. ⁱ Due to lack of raw data, the sexes could not be combined in this case, despite no obvious differences between the sexes in this study as well. ^j Data shown for comparative reasons only because CBD was applied in the form of a hemp mixture with other phytochemicals. ^k The study of Dziwenka et al. [9] was conducted with a hemp oil extract containing 28.14% cannabinoids and 25.2%

CBD. The levels were adjusted to reflect pure CBD. The dose-response models for males were questionable (data not shown).




Figure 1. Benchmark dose (BMD) modelling of cannabidiol (CBD) for centrilobular hypertrophy of the liver in a 26-week oral study in rats (GWTX1412, see Table 1): frequentist dichotomous Hill model with benchmark response (BMR) of 10% extra risk for the BMD and 95% lower confidence limit (BMDL).

From the animal study modelling results, the authors suggest to use the BMDL of 20 mg/kg bw/day from the GWTX1412 study in rats as POD, as this is the lowest, i.e., most conservative, value from the informative studies. The authors do not believe that the BMDL of the GWTX1413 study is meaningful because the dose-response model led to considerable extrapolation beyond the lowest non-zero dose. The other studies in hemp extracts confirm the correctness of the order of magnitude of the GWTX1412 data because the BMDL values were quite similar considering the uncertainties of BMD modelling efforts.

None of the human studies reported by the EFSA NDA panel [7] was sufficient for dose-response modelling. Therefore, the lowest LOAEL of 4.3 mg/kg bw/day, specifically highlighted by the EFSA panel in their presentation [16], was used as POD. The original study from which the EFSA NDA panel derived this LOAEL was a randomized clinical trial in 120 healthy male and female healthcare professionals receiving 300 mg of CBD for 28 days. Four participants (6.8%) had elevated levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (1 critical and 3 mild) [17].

The PODs from animal and human data were then used to estimate health-based guidance values (HBGV) using suitable uncertainty factors (Table 2). Overall, the authors suggest to use the human HBGV of 0.14 mg/kg bw/day for preliminary risk assessment, as it is more conservative than the animal HBGV and human data should be preferred in any case. Nevertheless, as both animal and human HBGV are in excellent agreement, the animal data provide independent validation of the correct magnitude of the human HBGV.

Table 2. Calculation of reference doses (RfD) for cannabidiol (CBD) based on animal and human data.

CBD	Animal data	Human data
Type of point of departure (POD)	BMDL, see Table 1	LOAEL [7,17]
Value of point of departure (POD)	20 mg/kg bw/day (1,400 mg/day ^a)	4.3 mg/kg bw/day (300 mg/day ^a)
Uncertainty factor (UF)	100 ^b	30 ^c
Reference dose (RfD)	0.20 mg/kg bw/day (14 mg/day ^a)	0.14 mg/kg bw/day (10 mg/day ^a)

^a Calculation for a 70-kg human standard weight [18]. ^b Default UF of 100 (10 for inter-species variability x 10 for intra-human variability [18]). ^c Overall UF of 30 (3 for extrapolation from the LOAEL to a NOAEL x 10 for intra-human variability, as previously suggested by EFSA for tetrahydrocannabinol (THC) [19].

4. Discussion

Despite the lack of data on CBD safety, correctly specified by the EFSA NDA panel [7] and also in a recent review by Nyland and Moyer [6], the authors believe that the available data allow to make at least a preliminary risk assessment if the dose-response information contained in the available data is appropriately considered. The authors also believe that the principle of precautionary public health protection demands the use of that data. The authors have previously commented regarding THC contamination of CBD products that it is short of a “scandal” because unapproved and potentially unsafe products are placed on the food market within the EU [20]. Other authors similarly characterised the CBD market as containing “black sheep” disregarding regulations trying to make a quick profit with the hype surrounding cannabis legalisation [21].

This preliminary risk assessment of available bioassays and human data on CBD toxicity strengthens this assessment, as many products on the market would be exceeding the estimated HBGV of 10 mg/day. For example, there are several CBD oil products on the market containing 10% of CBD, which means that the HBGV would be contained in an amount of 0.1 g, which is typically contained in only 3–4 drops of the product. The usually recommended dosage of several drops per day may, therefore, exceed the HBGV. For some products, which may contain even higher concentrations of CBD, the possible intake can even exceed the LOAEL of about 300 mg/day.

The HBGV of 10 mg/day proposed in this article is very similar to another approach for risk assessment by the Swiss Federal Food Safety and Veterinary Office (FSVO) determining an oral daily dose of 12 mg CBD/adult, which should not be exceeded [22]. The FSVO based its recommendation on a healthy volunteer phase I study, in which 5 out of 12 healthy subjects developed ALT elevations above the normal range at 5 mg/kg/day during the three-week treatment period [23]. The FSVO has used an uncertainty factor of 30, similar to the proposal in this study (Table 2), to calculate the guidance value.

The liver effects that are consistently observed in all tested species, including humans, are clearly a major cause for concern. It must be considered that this risk assessment concerns foods, for which safety must be generally guaranteed, unlike medicinal products for which risk-benefit considerations must be included. For CBD-containing foods, it must also be considered that they may be consumed daily a life-long without medical supervision or any form of nutrivigilance, which is not mandatory in the EU.

Meanwhile, the authors suggest that CBD products still available on the EU food market despite the lack of authorisation must be assessed if they might be “unsafe” in the sense of Article 14 (1) of the Basic Food Regulation No 178/2002 [24]. If they exceed the HBGV, they would be “unfit for consumption” (Article 14(1) and 14 (2) (b) of the Basic Regulation [24] or corresponding national regulations such as §12 of the German food and feed law). Products in exceedance of the human LOAEL of 4.3 mg/kg bw/day should be

considered as being “injurious to health” (Article 14(1) and (2) (a) of the Basic Regulation [24]) and they should also be considered as being a serious risk to health in the sense of the criteria for the EU Rapid Alert System for Food and Feed (RASFF), similar to the practice for THC risk assessment [25].

5. Conclusions

There is clearly a growing consumer demand for CBD and other cannabinoid products, which has not been adequately followed up by policy leading to a huge market of unregulated CBD food supplement products, which are also marketed in the supposed legal loopholes as cosmetic mouth sprays, non-food flavours or even phantasy products for mythical animals [26]. This situation is completely unsatisfactory for consumers, industry and control authorities alike. The unregulated market also leads to safety problems beyond cannabinoids, e.g., contamination with pesticides, heavy metals, or microbiological risks, or even the addition of synthetic cannabinoids [6]. Apart from that, quality control is lacking leading to inconsistent labelling making dosing unpredictable [27].

As the EFSA NDA panel has convincingly highlighted the lack of data necessary for final risk assessment, novel food approval could still take years, including the time required to conduct the chronic toxicity studies for the missing endpoints in the low-dose range expected in foods. The authors would now expect a response by the risk management of the European Commission and national authorities, how to go forward during the years until the completion of the novel food applications. Continuation of the complete prohibition of CBD food supplements is obviously not a considerate policy, as this has not worked in the past 5 years and consumers are still ingesting CBD in considerable amounts. The authors currently can envision at least 3 pathways to proceed: (i) low-dose CBD food supplements (up to 10 mg/day and less than 300 mg/package) could be approved in an intermediary basis including warning labels about the potential toxic effects (see the post-brexit UK approach), (ii) regulation of low-dose CBD products as over-the-counter medicinal products only available in pharmacies, as an additional category to the already available prescription-based high-dose CBD medicinal products (see suggestion by Health Canada [28]), or (iii) regulation of CBD products outside the scope of foods or medicines inside a separate framework, e.g., within the currently planned controlled distribution of cannabis to adults for recreational use in licensed stores in Germany. This is now a political decision to be made and the authors hope that the legislator does not again turn a blind eye to the problem as in the past.

Supplementary Materials: BMDS 3.0 analysis reports S1: GWTX1412; S2: GWTX1413; S3: Marx et al. 2018 (males); S4: Marx et al. 2018 (females); S5: Dziwenka et al. 2021.

Author Contributions: Conceptualization, D.W.L. and C.S.; methodology, D.W.L.; software, D.W.L.; validation, D.W.L.; formal analysis, D.W.L.; investigation, D.W.L.; resources, S.G.W.; data curation, D.W.L.; writing—original draft preparation, D.W.L.; writing—review and editing, C.S., P.G. and S.G.W.; visualization, D.W.L.; supervision, D.W.L.; project administration, D.W.L.; funding acquisition, S.G.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Publicly available datasets were analysed in this study. This data can be found here: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf (accessed 29 July 2022).

Acknowledgments: Janin Gerstenlauer and Tabea Dietz are thanked for help in the retrieval of FDA data on cannabidiol. The graphical abstract was AI-generated using the phrase “a bottle of cannabidiol oil and a hemp leaf in front of a stop sign” using DALL-E 2 on OpenAI.com.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lachenmeier, D.W.; Rajcic de, R.T.; Schwarz, S. An update on sustainable valorization of coffee by-products as novel foods within the European Union. *Biol. Life Sci. Forum* **2021**, *6*, 37. doi:10.3390/Foods2021-10969
2. European Parliament and the Council of the European Union. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. *Off. J. Europ. Union* **2015**, *L327*, 1-22.
3. Lachenmeier, D.W.; Rajcic de Rezende, T.; Habel, S.; Bock, V.; Sproll, C.; Walch, S.G. Current case law confirms novel food classification of hemp extracts and cannabidiol (CBD) in foods – narcotic classification of cannabis foods remains unclear. *Deut. Lebensm. Rundsch.* **2020**, *116*, 111-119. doi:10.5281/zenodo.3631608
4. Dräger, H.; Barthlott, I.; Golombek, P.; Walch, S.G.; Lachenmeier, D.W. Time trends of tetrahydrocannabinol (THC) in a 2008-2021 German national survey of hemp food products. *Foods* **2022**, *11*, 486. doi:10.3390/foods11030486
5. PontEurope. *The Budding CBD Industry in Europe*; Available online: <https://www.ponteuropa.com/gb/news-gb/the-budding-cbd-industry-in-europe/>: (accessed on 29 July 2022), 2022
6. Nyland, C.; Moyer, D.C. Regulating for safety: cannabidiol dose in food. *J. Food Prot.* **2022**, *85*, 1355-1369. doi:10.4315/JFP-21-374
7. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck, D.; Bohn, T.; Castenmiller, J.; De Henauw, S.; Hirsch-Ernst, K.I.; Maciuk, A.; Mangelsdorf, I.; McArdle, H.J.; Naska, A.; Pelaez, C.; Pentieva, K.; Siani, A.; Thies, F.; Tsabouri, S.; Vinceti, M.; Cubadda, F.; Frenzel, T.; Heinonen, M.; Marchelli, R.; Neuhäuser-Berthold, M.; Poulsen, M.; Prieto Maradona, M.; Schlatter, J.R.; Trezza, V.; van Loveren, H.; Albert, O.; Dumas, C.; Germini, A.; Gelbmann, W.; Kass, G.; Kouloura, E.; Noriega Fernandez, E.; Rossi, A.; Knutsen, H.K. Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. *EFSA J.* **2022**, *20*, 7322. doi:10.2903/j.efsa.2022.7322
8. Watkins, P.B.; Church, R.J.; Li, J.; Knappertz, V. Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase I clinical trial. *Clin. Pharmacol. Ther.* **2021**, *109*, 1224-1231. doi:10.1002/cpt.2071
9. Dziwenka, M.; Dolan, L.; Mitchell, J. Toxicological safety of VOHO hemp oil; a supercritical fluid extract from the aerial parts of hemp. *PLoS One* **2021**, *16*, e0261900. doi:10.1371/journal.pone.0261900
10. Hindelang, P.; Scharinger, A.; Richling, E.; Walch, S.G.; Lachenmeier, D.W. Using the BMD approach to derive acceptable daily intakes of cannabidiol (CBD) and tetrahydrocannabinol (THC) relevant to electronic cigarette liquids. *Front. Biosci. (Landmark Ed.)* **2022**, *27*, 228. doi:10.31083/j.fbl2708228
11. Davis, J.A.; Gift, J.S.; Zhao, Q.J. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDs) version 2.1.1. *Toxicol. Appl. Pharmacol.* **2011**, *254*, 181-191. doi:10.1016/j.taap.2010.10.016
12. United States Environmental Protection Agency. *About Benchmark Dose Software (BMDs) - Version 3.2*; Available online: <https://www.epa.gov/bmds/about-benchmark-dose-software-bmds-version-3201>: (Accessed: 24 June 2022), 2022
13. FDA. *Drug Approval Package: Epidiolex (Cannabidiol). Company: GW Research Ltd. Application Number: 210365 Orig 1. FDA Application Review Files. Pharmacology Review(s); Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf*: (accessed 29 July 2022), 2018
14. Marx, T.K.; Reddeman, R.; Clewell, A.E.; Endres, J.R.; Beres, E.; Vertesi, A.; Glavits, R.; Hirka, G.; Szakonyine, I.P. An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp. *J. Toxicol.* **2018**, *2018*, 8143582. doi:10.1155/2018/8143582
15. Dziwenka, M.; Coppock, R.; Alexander, M.; Palumbo, E.; Ramirez, C.; Lermer, S. Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in Sprague-Dawley rats. *Toxicol. Rep.* **2020**, *7*, 376-385. doi:10.1016/j.toxrep.2020.02.014
16. EFSA. *Information session for applicants on "The safety of cannabidiol as a novel food: data gaps and uncertainties"*; Available online: <https://www.efsa.europa.eu/sites/default/files/2022-07/Infosessio-CBD-slides.pdf>: (accessed on 29 July 2022), 2022
17. Crippa, J.A.S.; Zuardi, A.W.; Guimaraes, F.S.; Campos, A.C.; de Lima, O.F.; Loureiro, S.R.; Dos Santos, R.G.; Souza, J.D.S.; Ushirohira, J.M.; Pacheco, J.C.; Ferreira, R.R.; Mancini Costa, K.C.; Comparin, D.S.; Scarante, F.F.; Pires-Dos-Santos, I.; Mechoulam, R.; Kapczinski, F.; Fonseca, B.A.L.; Esposito, D.L.A.; Pereira-Lima, K.; Sen, S.; Andraus, M.H.; Hallak, J.E.C. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. *JAMA Netw. Open* **2021**, *4*, e2120603. doi:10.1001/jamanetworkopen.2021.20603
18. EFSA Scientific Committee. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. *EFSA J.* **2012**, *10*, 2579. doi:10.2903/j.efsa.2012.2579
19. EFSA Panel on Contaminants in the Food Chain (CONTAM). Scientific opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. *EFSA J.* **2015**, *13*, 4141. doi:10.2903/j.efsa.2015.4141
20. Lachenmeier, D.W.; Habel, S.; Fischer, B.; Herbi, F.; Zerbe, Y.; Bock, V.; Rajcic de, R.T.; Walch, S.G.; Sproll, C. Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? *F1000 Res.* **2021**, *8*, 1394. doi:10.12688/f1000research.19931.4

21. Kruse, D.; Beitzke, B. Comment on Lachenmeier et al (2020) "Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?": disputation on various points in the publication. *F1000 Res.* **2020**, *9*, 900. doi:10.12688/f1000research.25354.1
22. Federal Food Safety and Veterinary Office FSVO. *Briefing Letter Cannabidiol (CBD) in foods and the effects on the liver (in German)*; Available online: <https://www.blv.admin.ch/dam/blv/en/dokumente/lebensmittel-und-ernaehrung/publikationen-forschung/briefing-letter-lebensmittel-lebereffekte.pdf.download.pdf/Briefing%20Letter%20Cannabidiol%20in%20Lebensmitteln%20und%20Lebereffekte%20DE.pdf>; (accessed on 29 July 2022), 2021
23. FDA. *Comment from GW Pharmaceuticals. Posted by the Food and Drug Administration on Jul 19, 2019. GW Pharmaceuticals' submission on scientific data and information about products containing cannabis or cannabis-derived compounds. Document ID FDA-2019-N-1482-4257*; Available online: https://downloads.regulations.gov/FDA-2019-N-1482-4257/attachment_1.pdf; (accessed in 29 July 2022), 2019
24. European Parliament and Council. Regulation (EC) No 178/2002 of the European Parliament and of the council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. *Off. J. Europ. Comm.* **2002**, *L31*, 1-24.
25. Schweikle, S.; Golombek, P.; Sproll, C.; Walch, S.G.; Lachenmeier, D.W. The challenge of risk assessment of tetrahydrocannabinol (THC) in cannabidiol (CBD) oils and food supplements: an approach for deriving maximum limits. *Challenges* **2022**, *13*, 32. doi:10.3390/challe13020032
26. Lachenmeier, D.W.; Golombek, P.; Walch, S.G. Hanfhaltige Lebensmittel. Weiteres Update zur Verkehrsfähigkeit nach Entscheidungen des EuGH und BGH. *Deut. Lebensm. Rundsch.* **2021**, *117*, 481-487. doi:10.5281/zenodo.5746739
27. Miller, O.S.; Elder, E.J., Jr.; Jones, K.J.; Gidal, B.E. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. *Epilepsy Behav.* **2022**, *127*, 108514. doi:10.1016/j.yebeh.2021.108514
28. Health Canada. *Review of cannabidiol. Report of the science advisory committee on health products containing cannabis*; Health Canada: Ottawa, ON, Canada, 2022